

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/222322 A1

(51) International Patent Classification:

A61K 38/18 (2006.01) *A61P 9/12* (2006.01)
A61K 47/68 (2017.01) *C07K 14/475* (2006.01)
A61P 11/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2021/029492

(22) International Filing Date:

27 April 2021 (27.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/016,942 28 April 2020 (28.04.2020) US
63/159,253 10 March 2021 (10.03.2021) US

(71) Applicant: **ACCELERON PHARMA INC.** [US/US];
128 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: **LI, Gang**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **KUMAR, Ravindra**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **LU, Jonathan Toshi**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **JOSHI, Sachindra**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US). **ANDRE, Patrick**; c/o Acceleron Pharma Inc., 128 Sidney Street, Cambridge, MA 02139 (US).

(74) Agent: **VARMA, Anita** et al.; White & Case LLP, 75 State Street, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION

(57) Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.



WO 2021/222322 A1